Back to top

CRDF: Analyst Lowers Price Target, Maintains Buy Rating | CRDF Stock News

CRDF: Analyst Lowers Price Target, Maintains Buy Rating | CRDF Stock News

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Cardiff Oncology, Inc. (CRDF)